-

Pfizer Declares Third-Quarter 2020 Dividend

Board of Directors approves quarterly cash dividend of $0.38 per share

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of record at the close of business on July 31, 2020. The third-quarter 2020 cash dividend will be the 327th consecutive quarterly dividend paid by Pfizer.

Pfizer Inc.: Breakthroughs that change patients’ lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Contacts

Pfizer Media:
Amy Rose
(212) 733-7410
Amy.Rose@pfizer.com

Pfizer Investor:
Ryan Crowe
(212) 733-8160
Ryan.Crowe@pfizer.com

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Pfizer Media:
Amy Rose
(212) 733-7410
Amy.Rose@pfizer.com

Pfizer Investor:
Ryan Crowe
(212) 733-8160
Ryan.Crowe@pfizer.com

More News From Pfizer Inc.

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421). BRAFTOVI in combination with cetuximab and mFOLFOX6 was granted...

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and we...

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically sig...
Back to Newsroom